Format

Send to

Choose Destination
See comment in PubMed Commons below
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6.

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Author information

1
University of Alabama at Birmingham.
2
American University of Beirut, Beirut, Lebanon, and McMaster University, Hamilton, Ontario, Canada.
3
Tufts Medical Center, Boston, Massachusetts.
4
Beth Israel Deaconess Medical Center, Boston, Massachusetts.
5
University of California, Los Angeles.
6
Washington University School of Medicine, St. Louis, Missouri.
7
University of California, San Diego.
8
University of Nebraska Medical Center, Omaha.
9
North Mississippi Medical Center, Tupelo.
10
Healthy Motivation, Santa Barbara, California.
11
Mayo Clinic, Rochester, Minnesota.
12
University of Minnesota and Park Nicollet Clinic, St. Louis Park.
13
NorthShore University Health System, Evanston, Illinois.
14
Global Healthy Living Foundation, New York, New York.
15
Duke University Medical Center, Durham, North Carolina.
16
Rheumatology Consultants of Oregon, West Linn.
17
American College of Rheumatology, Atlanta, Georgia.

Abstract

OBJECTIVE:

To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA).

METHODS:

We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.

RESULTS:

The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional.

CONCLUSION:

This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.

PMID:
26545825
DOI:
10.1002/acr.22783
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center